Trivitron acquires Ani Lab for Euro 15.8 million

Trivitron Healthcare today announced the 100% acquisition of Ani labsystem, a leader in the In Vitro Diagnostic space with its presence in Neonatal Screening and Cardiac Bio markers screening areas. Ani Labsystems is a group of companies consist of Ani Biotech, Ani Labsystems, Biopoint and K3. Trivitron is acquiring all these four group companies and the merger is known as Labsystems Diagnostics OY- A Trivitron Group Company.

This global joint venture brings forth access to global manufacturing facility, a first of its kind for an Indian Medical Technology Company to go abroad for acquisition. While Neonatal Screening, Cardiac Biomarkers , Gastro and Respiratory diagnostics kits will continue to be manufactured in Finland, the Infectious Diseases and Women's health manufacturing will be shifted to The Trivitron Medical Technology Park based in Chennai, according to company's statement.

With this acquisition, Trivitron has the capability to enter into Point of Care Diagnostics, Immuno Diagnostics and Molecular Diagnostics, the three of the fastest growing areas in the In Vitro Diagnostics field. Trivitron is already manufacturing Hematology and Clinical Chemistry kits from their Facilities. Hence this will make Trivitron a global In Vitro Diagnostic  company with capability of manufacturing variety of Diagnostics Kits covering all major areas of In Vitro Diagnostics Field. In Chennai, Trivitron Healthcare has established South Asia’s first state-of-art medical technology manufacturing facility -The Trivitron Medical Technology Park and Trivitron’s innovation center at the IIT Madras.

The Trivitron Medical Technology Park enables cost effective manufacturing as per international standard in India.

“The factory based in India will enable Trivitron’s access to new infectious disease testing products for emerging markets and offer their customers new value oriented product lines in South Asia, South East Asia, Middle East and Africa,” commented G S K. Velu, Founder and Managing Director of Trivitron Healthcare. 

“With a 15.8 million EURO foreign direct investment into Finland, the financial position of Ani Labsystems will be clearly strengthened. Ani Labsystems is the manufacturer of infectious disease laboratory diagnostics and neonatal screening since 30 years and Ani Biotech, the pioneering innovator and producer of home and point-of-care tests for cardiac, fertility, gastroenterology and infectious disease biomarkers for 25 years” says President Mika Saramaki.